Table 2.
A. Baseline survey data for the three study sites. B. Follow-up survey data for three study sites.
| A. Baseline survey data for the three study sites | ||||||
|---|---|---|---|---|---|---|
| Site | Malindi, Kenya | Nanaha, PNG | Pondicherry, India | |||
| Vector Genus | Anopheles | Anopheles | Culex | |||
| ABR | – | 11611 | 26400 | |||
| Baseline Year | 2002 |
1994 |
1981 |
|||
| Age Group | Sample Size | Mf Prevalence (%) | Sample Size | Mf Prevalence (%) | Sample Size | Mf Prevalence (%) |
| <10 | 135 | 6.7 | 28 | 39.3 | 2651 | 4.3 |
| 10–20 | 225 | 15.6 | 56 | 44.6 | 4560 | 10.2 |
| 20–30 | 115 | 24.3 | 50 | 56.0 | 3422 | 11.3 |
| 30–40 | 94 | 22.3 | 28 | 64.3 | 2033 | 8.4 |
| 40–50 | 77 | 35.1 | 21 | 57.1 | 1364 | 8.4 |
| 50–60 | 41 | 39.0 | 20 | 75.0 | 806 | 8.9 |
| 60+ | 36 | 33.3 | 8 | 87.5 | 589 | 7.8 |
| Overall | 723 | 20.5 | 211 | 55.0 | 15425 | 8.9 |
| B. Follow-up survey data for three study sites. | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Site | Malindi, Kenya | Nanaha, PNG | Pondicherry, India | |||||||||
| Intervention | DEC + ALBa MDA |
DEC + IVRa MDA |
Integrated vector management |
|||||||||
| Follow-Up Year | Sample Size | Mf Prevalence (%) | MDA coverage (%) |
Follow-Up Year | Sample Size | Mf Prevalence (%) | MDA coverage (%) |
Follow-Up Year | Sample Size | Mf Prevalence (%) | IVM coverage (%) | |
| 2003 | 461 | 11.3 | 83.4 | 1995 | 238 | 48.3 | 71.6 | 1986 | 22464 | 6.4 | 0b | |
| 2004 | 484 | 7.2 | 80.3 | 1996 | 208 | 27.4 | 65.8 | 1989 | 20416 | 5.6 | 0b | |
| 1997 | 196 | 13.3 | 62.8 | 1992 | 15885 | 5.0 | 0b | |||||
| 1998 | 221 | 0.9 | 66.8 | |||||||||
| 1999 | 166 | 0.6 | 49.4 | |||||||||
a
Diethylcarbamazine (DEC), albendazole (ALB), ivermectin (IVR).
b
Integrated Vector Management (IVM) was active in Pondicherry 1981–1985. Declines in mf prevalence were observed in the years following.